Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Leukemia

Volumn 28, Issue 7, 2014, Pages 1529-1536

  Berenson, J R ^a,b,c   Hilger, J D ^b   Yellin, O ^b   Dichmann, R ^d   Patel Donnelly, D ^d   Boccia, R V ^e   Bessudo, A ^f   Stampleman, L ^g   Gravenor, D ^h   Eshaghian, S ⁱ   Nassir, Y ^j   Swift, R A ^c   Vescio, R A ⁱ  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b Oncotherapeutics   (United States)

^c James R Berenson MD Inc   (United States)

^d Department of Medical Oncology and Hematology Central Coast Medical Oncology ^*  (United States)

^e Center for Cancer and Blood Disorders   (United States)

^f Department of Medical Oncology Hematology California Cancer Associates for Research and Excellence   (United States)

^g Pacific Cancer Care Department of Medical Oncology and Hematology   (United States)

^h Family Cancer Center   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j Women's Cancer Research Institute   (United States)

more..

Author keywords

bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; refractory; relapsed

Indexed keywords

ASCORBIC ACID; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CLARITHROMYCIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; STEROID; THALIDOMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED ANEMIA; CHILL; CLINICAL ARTICLE; DEHYDRATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; INFLUENZA; JAW OSTEONECROSIS; KIDNEY FAILURE; LEUKOPENIA; LIVER INJURY; LYMPHOCYTOPENIA; MIGRAINE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RECTUM HEMORRHAGE; SEPSIS; TACHYCARDIA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; OLIGOPEPTIDES; PYRAZINES; TREATMENT OUTCOME;

EID: 84904054234     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.27     Document Type: Article

References (37)

1. Cancer Facts & Figures. Am Cancer Soc 2013.
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 111 2516-2520.
3. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib a multicenter international myeloma working group study. Leukemia 2012 26 149-157.
4. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012 120 2817-2825.
5. Onix Pharmaceuticals, Inc. South San Francisco C. Krypolis Prescribing Information 2013.
6. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012 158 739-748.
7. Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011 118 1763-1765.
8. Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 2009 84 657-660.
9. Taverna C, Voegeli J, Trojan A, Olie Ra, von Rohr A. Effective response with bortezomib retreatment in relapsed multiple myeloma-a multicentre retrospective survey in Switzerland. Swiss Med Wkly 2012 142 w13562.
10. Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 2013 160 649-659.
11. Berenson JR, Yellin O, Kazamel T, Hilger JD, Chen C-S, Cartmell a et al. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia 2012 26 1675-1680.
12. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013 160 321-330.
13. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011 17 5311-5321.
14. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007 110 3281-3290.
15. Fenical W, Jensen PR, Palladino MA, Lam KS, Lloyd GK, Potts BC. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem 2009 17 2175-2180.
16. Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S et al. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leuk Res 2012 36 1422-1427.
17. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012 120 1801-1809.
18. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013 122 3122-3128.
19. BladÉ J, Samson D, Reece D, Apperley J, BJÖ rkstrand B, Gahrton Gö et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998 102 1115-1123.
20. Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006 20 1467-1473.
21. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996 17 343-346.
22. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R et al. Integrated safety profile of single-agent carfilzomib experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013 98 1753-1761.
23. Korde N, Zingone A, Kwok M, Manasanch EE, Costello R, Zuchlinski D et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. ASH Annu Meet Abstr 2012 120 732.
24. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 2013 19 2248-2256.
25. Badros AZ, Papadopoulos KP, Zojwalla N, Lee JR, Siegel DSA. Phase 1b study of 30-minute infusion carfilzomib 20/45 and 20/56 mg/m2 plus 40mg weekly dexamethasone in patients with relapsed and/or refractory (R/R) multiple myeloma. ASH Annu Meet Abstr 2012 120 4036.
26. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH Annu Meet Abstr 2012 120 74.
27. Touzeau C, Kolb B, Hulin C, Caillot D, Benboubker L, Tiab M et al. Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM) results of a phase (Ph) I/II trial. J Clin Oncol 2013 31 8513.
28. Palumbo A, Bringhen S, Villani O, Siniscalchi A, Russo E, Uccello G et al. Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients. ASH Annu Meet Abstr 2012 120 730.
29. Sonneveld P, Asselbergs E, Zweegman S, Van der Holt B, Kersten MJ, Vellenga E et al. Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate. ASH Annu Meet Abstr 2012 120 333.
30. Mikhael JR, Reeder CB, Libby ENI, Costa LJ, Bergsagel PL, Buadi F et al. Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. ASH Annu Meet Abstr 2012 120 445.
31. Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009 27 5713-5719.
32. Richardson PG, Jagannath S, Jakubowiak AJ, Lonial S, Raje N, Alsina M et al. Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed/refractory multiple Myeloma (MM) updated efficacy and safety data after 42 years of follow-up. ASH Annu Meet Abstr 2010 116 3049.
33. Groll M, Kim KB, Kairies N, Huber RCC. Crystal structure of epoxomicin20S proteasome reveals a molecular basis for selectivity of a0 ,b0-epoxyketone proteasome inhibitors. J Am Chem Soc 2000 122 1237-1238.
34. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007 67 6383-6391.
35. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A et al. Bortezomib-resistant myeloma cell lines a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010 24 1506-1512.
36. Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008 143 537-540.
37. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010 116 4745-4753.